Treatment of advanced small cell lung cancer. Clinical case and literature review

Abstract

Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung cancer (SCLC) is one of the most prognostically unfavorable malignant tumors in humans. About 15% of lung tumors are SCLC. The first combination for the treatment of advanced SCLC after etoposide and platinum preparations was the combination of the etoposide + carboplatin (EP) regimen with atezolizumab. In the IMpower133 study, after a median follow-up of 13.9 months. median overall survival in the atezolizumab group was 12.3 months, and in the placebo group 10.3 months. In clinical observation, the effectiveness of the combination of the EP regimen with atezolizumab has been demonstrated. A patient with SCLC received 4 courses of EP therapy with atezolizumab and 14 injections of atezolizumab. The partial response achieved is retained. Case study efficacy and satisfactory safety profile of the combination of atezolizumab and the EP regimen.